- CEO
- Yong Jun Tu
- Full Time Employees
- 4,686
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Huangyan Jiangkou Chemical Dev Zn Taizhou ZH China 318020
- IPO Date
- Sep 19, 2017
- Business
- Zhejiang Tianyu Pharmaceutical Co., Ltd. (300702.SZ) engages in the research, development, production, and sale of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and formulations, primarily targeting chronic disease treatments including cardiovascular, anti-diabetic, anti-atherosclerosis, anticoagulant, anti-asthmatic, and anti-cancer therapies; core products encompass sartan antihypertensives such as azilsartan, azilsartan medoxomil potassium, candesartan cilexetil, irbesartan, losartan potassium, olmesartan medoxomil, telmisartan, and valsartan; hypoglycemics including canagliflozin hemihydrate, dapagliflozin, empagliflozin, sitagliptin hydrochloride monohydrate, and vildagliptin; anticoagulants such as apixaban, dabigatran etexilate mesylate, and avatrombopag maleate; antihyperlipidemics like sacubitril valsartan sodium; anti-asthmatics including nebivolol hydrochloride; and oncology APIs such as cabozantinib malate, enzalutamide, ibrutinib, apalutamide, and ribociclib succinate, alongside fine chemicals, CDMO services from clinical phase I to commercial production, and comprehensive process development with CEP/DMF documentation and cGMP/EU GMP compliance. Founded in 1993 with roots in Zhejiang Huangyan Tianyu Chemical Plant and formally registered in 2003, the company is headquartered in Taizhou, Zhejiang Province, China, with additional production bases and R&D centers in Shanghai, Hangzhou, Yancheng, Weifang, and Changzhou; it operates as a national high-tech enterprise and intellectual property demonstration entity, supplying products to leading original and generic pharmaceutical companies in over 70 countries worldwide. Recent developments include approval of a cash dividend for 2024 payable in June 2025, authorization of a share buyback plan in January 2024, participation in private placement financing activities in 2023 involving investors such as Shenzhen Investment Control East China Sea Investment Co., Ltd. and others totaling significant capital infusions, expansion of its API portfolio with new offerings like aprocitentan, brexpiprazole, and elacestrant dihydrochloride, and receipt of an FDA warning letter in February 2025 regarding CGMP compliance for APIs.